Page last updated: 2024-10-30

labetalol and Thrombopenia

labetalol has been researched along with Thrombopenia in 1 studies

Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.

Research Excerpts

ExcerptRelevanceReference
"Labetalol was discontinued on day 8, but no additional significant rise occurred."1.33Suspected beta-antagonist-induced thrombocytopenia. ( Jenkins, JK; Stamm, PL; Vigrass, HG, 2005)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stamm, PL1
Jenkins, JK1
Vigrass, HG1

Other Studies

1 other study available for labetalol and Thrombopenia

ArticleYear
Suspected beta-antagonist-induced thrombocytopenia.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:3

    Topics: Adrenergic beta-Antagonists; Adult; Female; Humans; Labetalol; Lupus Erythematosus, Systemic; Nadolo

2005